A study on patients with HER2+ metastatic BC found that young patients were more likely to receive PH+taxane than older patients, and older patients were more likely to receive regimens with H without P or hormone therapy, and the results showed that young patients have better CSS than older patients [37]. This evidence concerns the gene ERBB2 and breast cancer.